Product Description
Amphotericin B deoxycholate belongs to the polyene class of antifungals. It is also known by the conventional name amphotericin B and has been used for the treatment of invasive fungal infections for more than 50 years. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK482327/)
Mechanisms of Action: Ergosterol Synthesis Antagonist,Sterol Synthesis Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, China, Korea, New Zealand, Thailand, Uganda, United States, Vietnam
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Aspergillosis|Candidiasis, Invasive|Communicable Diseases|Cryptococcosis|HIV Infections|Histoplasmosis|Meningitis, Cryptococcal|Meningitis, Fungal|Meningitis, Viral|Shock, Septic
Phase 1: Cystic Fibrosis|Febrile Neutropenia|Healthy Volunteers|Invasive Fungal Infections|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LAmB-FAST | P3 |
Not yet recruiting |
Meningitis, Viral|Meningitis, Cryptococcal|Meningitis, Fungal|HIV Infections|Histoplasmosis|Cryptococcosis |
2030-01-06 |
|
| ACACIA | P3 |
Recruiting |
Meningitis, Cryptococcal |
2027-10-01 |
|
| INDUCTION Trial | P3 |
Not yet recruiting |
Histoplasmosis|Communicable Diseases |
2025-11-28 |
|
| HF114-006 | P3 |
Not yet recruiting |
Aspergillosis|Candidiasis, Invasive |
2025-08-15 |
25% |